Skip to search.
 TSX Down 0.04% TSX Ventures Down 0.04%

Nektar Therapeutics (NKTR)

-NasdaqGS
11.00 Down 0.31(2.74%) Mar 31, 4:00PM EDT
|Pre-Market : 11.00 0.00 (0.00%) 4:21PM EDT - Nasdaq Real Time Price
Add to Portfolio
Prev Close:11.31
Open:11.22
Bid:8.08 x 100
Ask:11.60 x 300
1y Target Est:15.42
Beta:1.34
Earnings Date:May 5 - May 11 (Est.)
Day's Range:10.98 - 11.28
52wk Range:10.10 - 17.53
Volume:1,093,169
Avg Vol (3m):1,239,900
Market Cap:1.45B
P/E (ttm):N/A
EPS (ttm):-0.43
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Headlines

Comparison

Symbol% ChgMkt Cap
NKTRDown 2.74%1.45B
BMYDown 1.92%106.59B
ENZNUp 2.91%46.83M
GSKDown 2.22%111.01B

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):7.40
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-15) :-0.39
Quarterly EPS Est (Mar-15) :-0.40
Mean Recommendation*:1.8
PEG Ratio (5 yr expected):3.69

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback